Search Results

You are looking at 91 - 100 of 1,210 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Adam J. Kole, John M. Stahl, Henry S. Park, Sajid A. Khan, and Kimberly L. Johung

Station, TX). Table 1. Patient Cohort Demographic and Clinicopathologic Characteristics Results Within the NCDB, we identified 3,370 patients from 2004 to 2012 with histologically confirmed clinical T1N0 anal canal carcinoma

Full access

Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer, and Ines Vaz-Luis

−. Patients with >1 disease site were assigned to the category of the first site listed, according to a prespecified ranking system defined by importance. Table 1. Patient Demographics and Clinicopathologic Characteristics (n=302) Central

Full access

Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Fatima Nagib, Sandra Pérez-Aguilera, María Dejoz, Alberto Cabrera-Zubizarreta, Yolanda García-Hidalgo, Ana Estremera, and for the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis

years. Table 1 also shows the characteristics of the 203 patients whose clinical histories and images were selected for the study and of the 25 readers who interpreted their data. Table 1. Sample Characteristics As Table 2 shows, interobserver

Full access

Erin E. Hahn, Michael K. Gould, Corrine E. Munoz-Plaza, Janet S. Lee, Carla Parry, and Ernest Shen

adjusted for multiple pairwise comparisons between comorbidity classes by using the Bonferroni correction. Table 1. Patient Characteristics, Cancer Treatment, and Comorbidities Results We identified 7,803 patients with CRC ( Table 1

Full access

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group

summarize sample characteristics, analyze feasibility/acceptability, and summarize secondary outcomes. We compared self-efficacy scores preintervention and postintervention using multilevel models (MIXED function). Results Of 36 eligible and contactable

Full access

Ishveen Chopra, Malcolm D. Mattes, Patricia Findley, Xi Tan, Nilanjana Dwibedi, and Usha Sambamoorthi

service. Each individual was observed for 48 months ( Figure 1 ). Figure 1. Schematic of the study design. Each individual was observed for 48 months with a 24-month baseline (for identification of CAD and baseline characteristics), 12-month preindex, and

Full access

Carrie Zornosa, Jonathan L. Vandergrift, Gregory P. Kalemkerian, David S. Ettinger, Michael S. Rabin, Mary Reid, Gregory A. Otterson, Marianna Koczywas, Thomas A. D'Amico, Joyce C. Niland, Rizvan Mamet, and Katherine M. Pisters

Member Institution. Data collection includes patient, disease, and treatment characteristics that are manually abstracted from medical records by trained data managers at each participating site. Data are abstracted for each patient in 6-month intervals

Full access

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta

resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease

Full access

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

clinical variables. R version 3.6.1 (R Foundation for Statistical Computing) was used for statistical analyses. Results Patient Characteristics From 2001 through 2019, 68 clinical trials conducted at Gustave Roussy and Memorial Sloan Kettering

Full access

Seanthel Delos Santos, Noah Witzke, Bishal Gyawali, Vanessa Sarah Arciero, Amanda Putri Rahmadian, Louis Everest, Matthew C. Cheung, and Kelvin K. Chan

assessed at the time of primary publication and at 3 years post-FDA approval using all publicly available data in eligible subsequent publications. Results Characteristics of Included Studies Of 113 indications that met the eligibility criteria, there were